Protein phosphatases are critical components in cellular regulation; they do not only act as antioncogenes by antagonizing protein kinases, but they also play a positive regulatory role in a variety of cellular processes that require dephosphorylation. Thus, assessing the function of these enzymes necessitates the need for a robust, sensitive assay that accurately measures their activities. The authors present a novel, homogeneous, and nonradioactive assay to measure the enzyme activity of low concentrations of several protein phosphatases (phosphoserine/phosphothreonine phosphatases and phosphotyrosine phosphatases). The assay is based on the use of fluorogenic peptide substrates (rhodamine 110, bis-phosphopeptide amide) that do not fluoresce in their conjugated form, which is resistant to cleavage by aminopeptidases. However, upon dephosphorylation by the phosphatase of interest, the peptides become cleavable by the protease and release the highly fluorescent-free rhodamine 110. The assay is rapid, can be completed in less than 2 h, and can be carried out in multiwell plate formats such as 96-, 384-, and 1536-well plates. The assay has an excellent dynamic range, high signal-to-noise ratio, and a Z′ of more than 0.8, and it is easily adapted to a robotic system for drug discovery programs targeting protein phosphatases. (Journal of Biomolecular Screening 2004:223-231) 
T HE ROLE OF PROTEIN PHOSPHATASES in mediating the cellular responses to a wide variety of agonists and antagonists is well recognized; in fact, targeting these enzymes has attracted the attention of scientists in diverse fields of interest. These enzymes are implicated in a variety of cellular processes such as proliferation, differentiation, and apoptosis. More than 30% of all cellular proteins in the human proteome are subject to phosphorylation at 1 or more residues, and the family of protein kinases has been estimated to contain 575 kinase genes, or 2% of the genome, and about 130 phosphatases, representing an additional 0.5% of the genome. [1] [2] [3] [4] Protein phosphatases play a key role in cellular functions by not only antagonizing protein kinases but also activating them via the removal of an inhibitory phosphoryl moiety. 3, 4 In addition, biochemical and genetic studies indicate that protein phosphatases exert both positive and negative effects on signaling pathways and play crucial physiological roles in a variety of mammalian tissues and cells, and deregulation of their activity contributes to the pathogenesis of human diseases. 3, 4 Thus, these enzymes represent novel molecular targets for the development of new therapeutic drugs. To monitor the activity of these enzymes under a variety of experimental conditions and develop selective inhibitors of these enzymes for therapeutic applications, it is necessary to develop assays that are homogeneous, fast, and amenable to high-throughput screening (HTS) of a large number of library compounds. Early protein phosphatase assays were radioactive, relying on the liberation of radiolabeled phosphate from phosphorylated peptide or protein substrates, as well as the quantitation of the liberated radioactivity using liquid scintillation spectrometers. Nonradioactive assays were based on the quantitation of liberated phosphate and the formation of a colored complex with malachite green and acidified phosphomolybdate. 5 For a special group of phosphatases such as phosphotyrosine phosphatases, p-nitrophenyl phosphate (pNPP) is used as a substrate, and enzyme activity by colorimetric measurement of released p-nitrophenol is quantitated at 410 nm. 6 Still others used the increase in absorbance of the dephosphorylated tyrosine containing peptide substrate at 282 nm and reported the difference of the absorption coefficient (∆e) as a readout for phosphatase activity. 7 More recently, a sensitive fluorogenic substrate for protein tyrosine phosphatases using 3,6-fluorescein diphosphate as a substrate was reported. 8 Although each of these methods has merits, all have limitations that made them inadequate for HTS of a large number of compounds toward S/T protein phosphatases (PPases) and protein tyrosine phosphatases (PTPasaes). For example, the malachite green approach suffers from the lower detection limit, which is in the nmol range and thus requires a high amount of enzymes and high peptide substrate concentrations. In addition, the presence of inorganic phosphates in samples or solutions and glassware increases the background significantly, which might affect the accuracy of the results. The radioactivity-based assay suffers from dealing with radioactivity and the cost of disposing the radioactive waste. Although pNPP has been 1 of the most commonly used substrates for phosphatases, doubt was cast recently on its reliability as a substrate for newly discovered phosphatases. 9 It was reported that the mRNA transcription/processing factor, Ssu72, is related to low Mr PTPase and hydrolyzes pNPP but does not dephosphorylate phosphotyrosine peptide substrate. 9 This finding is critical for understanding the cellular functions of these phosphatases in the cellular environment. The increase in absorbance of the dephosphorylated tyrosine-based method is not suitable for substrates with multiple tyrosine phosphorylations because only the gross change in absorbance or fluorescence will be followed. In addition, the assay is limited when the peptide contains tryptophan or other proteinaceous material, which gives high background signals. The substrate 3,6-diphosphofluorescein is not only dephosphorylated by PTPases but can also be hydrolyzed by nonprotein phosphatases and other unrelated enzymes such as esterases and hydrolases. Most recently, 2 HTS assay systems for phosphatases were described: the first uses the fluorescence polarization (FP) principle, 10 and the other uses the fluorescence resonance energy transfer (FRET) approach. 11 In FP, the binding of phosphorylated tyrosine-containing peptide to antiphosphotyrosine antibodies results in an increase in the polarization of the fluorescent peptide. 10 Thus, in the presence of a PTPase, the phosphopeptide is dephosphorylated, and the free nonphosphorylated but fluorescently labeled peptide tumbles faster, resulting in a decrease in FP. The other system is FRET, which is based on a coupled-enzyme format using a differential protease sensitivity of phosphorylated versus nonphosphorylated peptide substrates. 11 Specifically, the method relies on the differential sensitivity of chymotrypsin to phosphorylated tyrosine or to phenylalanine or tyrosine adjacent to phosphorylated residues of phosphoserine or phosphothreonine. 11 Although the FP-based assay for PTPases is easier to develop due to the availability of specific antibodies for phosphotyrosine, similar assays for S/T PPases require the availability of equally highly selective and high-affinity antibodies, which have to be generated for each phosphopeptide because no high-affinity and selective phosphoserine or phosphothreonine antibodies are available. In addition, the labeling of the peptide with fluorescent compound introduces additional variability, which necessitates further optimization, and the binding of the phosphopeptide to the antibodies also might be altered by the reaction components. A direct FP assay does not give good dynamic range, and thus a competitive assay requires the ad-dition of a competing substrate to improve the assay performance. The need for generating specific and high-affinity antibodies in FP was recently circumvented when a cationic matrix that binds phosphorylated peptides was used instead of antibodies. 12 The use of the cationic matrix, however, suffers from the nonspecific interaction of acidic peptides, which behaves similar to the phosphopeptides and binds to the matrix; the assay also does not tolerate the presence of other negatively charged molecules such as inorganic phosphates. Although we routinely obtain a signal-tobackground ratio of 20 in our assay system, the maximum expected change in FP-based assays is 2-to 3-fold. This limitation also applies to the FRET-based assay, in which the signal-to-background ratio is significantly lower than our assay (1.7-fold dynamic range).
To address the various drawbacks of existing assays, we developed a novel and robust system to measure the enzyme activity of several protein phosphatases. The assay is rapid, can be completed in less than 2 h, and can be carried out in multiwell plate formats such as 96-or 384-well plates. The assay has an excellent dynamic range and is easily adapted to robotic systems for drug discovery programs.
MATERIALS AND METHODS

Reagents
Enzymes such as protein phosphatases and aminopeptidase were obtained from Promega Corp. (Madison, WI), Upstate Biotechnology (Lake Placid, NY), and Calbiochem-Novabiochem Corp. (San Diego, CA). Peptide substrates were synthesized by Synpep Corp. (Dublin, CA) using a peptide synthesizer and purified according to published protocols. In brief, the synthesis of the phosphopeptide substrate for S/T PPase (rhodamine 110 peptide conjugate RRApTVA-R110-AVpTARR) was carried out by first derivatizing rhodamine 110 by Boc-Ala at its 2 amino groups. Di-Ala-modified rhodamine 110 was readily obtained upon treatment of the Boc-Ala-derivatized rhodamine by acid treatment. Fully protected peptide Boc-Arg-Arg-Ala-pThr-Val, prepared via solidphase synthesis, was then coupled onto Di-Ala-rhodamine 110 by the standard activating procedure. The protected peptide rhodamine conjugate was then subjected to trifluoroacetic acid (TFA) cleavage and purified by high-performance liquid chromatography (HPLC), affording desired rhodamine 110 peptide conjugate. Other peptide substrates were synthesized similarly by making the dipeptide C-terminus amino acid-rhodamine 110, and then they were coupled to the fully protected phosphopeptide Boc form without the C-terminus amino acid and then cleaved with TFA and purified by HPLC. Phosphopeptide concentration was determined spectrophotometrically using ε = 51,000 M -1 cm -1 at 232 nm. Sequences of other peptides used in this study are AApYANAA-R110-AANApYAA for PTPases. The protease reagent (V309A) and stabilizer buffer (V306A) were both from Promega Corp. (Madison, WI). The first contains aminopeptidase (EC.3.4.11.2), and the latter contains α-actinonin. The composition of each is described next. All other reagents were purchased from Sigma-Aldrich Corp. (St. Louis, MO).
Methods
To illustrate the utility of the newly developed assay system, we tested several PPases such as protein phosphatase-1 (PP1); protein phosphatase 2A, 2B, and 2C (PP2A, PP2B, and PP2C); and several PTPases such as PTP1B, CD45, and Yop51. These enzymes were assayed using optimal assay conditions as described in the literature, without any modification with the appropriate substrate for each group of enzymes. The assays were performed at 25°C (room temperature) or at 30°C. Several selective enzyme inhibitors were tested; these included okadaic acid and inhibitor-2 for PPases and sodium vanadate for PTPases.
Typical enzyme reactions for PPases were carried out in a 50-µL volume that contained 40 mM Tris-HCl (pH 7.5), 0.1 mg/mL bovine serum albumin (BSA), and 5 µM R110-bis (RRApTVAamide) phosphatase substrate in black 96-well plates (flat bottom) and the enzyme of choice. Reactions also included additional components required for activation of the various phosphatases: PP2A (none), PP1 (1 mM MgCl 2 and 0.1 mM MnCl 2 ), PP2B (1 mM NiCl 2 , 1 mM CaCl 2 , and 1 µM calmodulin), and PP2C (20 mM MgCl 2 ). Reactions were carried out at 25°C for 10 min (PP1 and PP2A) or for 30 min (PP2B and PP2C). Reactions were terminated by the addition of a termination buffer that contained a sufficient amount of protease reagent (25 mU of aminopeptidase in 40 mM Tris-HCl [pH 7.5], 0.1 mg/mL BSA) and the selective inhibitor for each phosphatase. These are okadaic acid (1 µM for PP1 or 100 nM for PP2A), EGTA (33 mM) for PP2B, and ethylenediaminetetraacetic acid (EDTA) (33 mM) for PP2C. Reactions were incubated for an additional 90 min, and the protease reactions were terminated by the addition of 25 µL of stabilizer (10 uM αactinonin, 40 mM Tris-HCl [pH 7.5], 0.1 mg/mL BSA) if needed. Enzyme activity was measured by reading fluorescence using excitation at 485 nm and emission at 530 nm on a Cytofluor II fluorimeter, Perseptive BioSystems (Framingham, MA).
Determination of enzyme activity for PTPases was carried out in 50 µL of reaction containing 40 mM Tris-HCl (pH 7.5), 0.1 mg/ mL BSA, 5 µM R110-bis (AApYANAA-amide) PTPase phosphopeptide substrate, and the indicated amount of phosphatase (PTP1B, CD45, or Yop51) in solid black 96-well plates (flat bottom). Reactions were incubated for 30 min at 25°C and then were terminated by the addition of 25 µL of 300 µM Na 3 VO 4 and a sufficient amount of protease. The reactions were incubated for an additional 90 min at 25°C. Enzyme activity was measured by reading fluorescence in a fluorimeter using an excitation at 480 nm and fluorescence emission at 520 to 530 nm on a Cytofluor II fluorimeter, Perseptive BioSystems (Framingham, MA).
RESULTS
Principle of the assay
It has been previously reported that phosphorylation of peptides on serine 13 or tyrosine 14 decreases the proteolytic activity of proteases and that phosphorylation of peptides by protein kinases can be monitored by the increase in resistance to protease cleavage of the phosphorylated product. Based on these reports, it is expected that a phosphopeptide will not be amenable to cleavage by aminopeptidase as compared with the nonphosphorylated peptide homologue. Hence, the difference in cleavage rate of the peptide in the absence and presence of phosphorylation can be used as a measure of the kinase activity. The cleavage rate can be monitored by HPLC separation of the peptides before and after phosphorylation. Conversely, it is surmised that active phosphatases, by removing the phosphate moiety, will enhance the proteolytic activity of the protease. Thus, an increase in peptide cleavage can be directly used as a measure of phosphatase activity. Although this approach is valid in principle, it is not practical for a large number of samples; is tedious, time-consuming, and difficult to quantify; and requires a large amount of substrates and enzymes. In addition, for accurate assessment of enzyme activity, reaction products have to be separated from the substrates (HPLC, thin-layer chromatography [TLC], etc.), and a standard curve for the quantitation of phosphopeptide formed is needed. To develop a phosphatase assay based on this principle that is sensitive, simple, and scalable to high-throughput formats, we used a fluorescence technology based on the use of rhodamine 110-modified phosphopeptide substrates as shown below.
Rhodamine 110-based protein phosphatase phosphopeptide substrates
Free rhodamine 110 (R110) is a fluorescent molecule, but when covalently linked via both of its amino groups in a bisamide form, it results in suppression of both its visible absorption and fluorescence. Upon enzymatic cleavage, the nonfluorescent bisamide substrate is converted in a 2-step process, first to the fluorescent monoamide and then to the even more fluorescent free R110 (Fig.  1) . The fluorescence intensities of the monoamide and of free R110 are constant from pH 3 to 9. 15 Both of these hydrolysis products exhibit spectral properties similar to those of fluorescein, with peak excitation and emission wavelengths of 496 nm and 530 nm, respectively. Free R110 has intense visible absorption (∈ 496 nm 80,000 M -1 cm -1 in pH 6 solution). When the peptide substrate is in the phosphorylated form, it is resistant to cleavage by aminopeptidase. Based on this principle, it is expected that the phosphopeptide will be resistant to cleavage by the aminopeptidase, resulting in a minimal change in fluorescence. However, when the phosphoryl moiety is removed by a phosphatase, the peptide is cleaved, releasing free R110 and resulting in en-hanced fluorescence at 530 nm ( Fig. 1 ). Other aminopeptidases can be used as long as they are free of endopeptidase activity, and thus contamination with the commonly known proteases such as trypsin, chymotrypsin, and so forth should be avoided. To test our hypothesis, we synthesized R110, bis-phosphothreonine-containing peptide and R110, bis-phosphotyrosine-containing peptide to monitor the enzyme activity of PPases (PP1, PP2A, PP2B, and PP2C), and PTPases (PTP1B, CD45, and Yop51), respectively.
Phosphatase assay with serine/threonine protein phosphatases (PPases)
To test our hypothesis and confirm that phosphorylation of peptide substrates inhibits the proteolytic activity of an aminopeptidase, we synthesized 2 bisamide R110-linked peptides, a nonphosphorylated and phosphorylated form of the peptide. We tested the cleavage efficiency of the peptidase for each peptide separately and with a mixture of the 2 peptides at different ratios of the phosphorylated form and the nonphosphorylated form, keeping the total concentration of the 2 peptides constant. It is evident from the results shown in Figure 2 that the fluorescence output increases when the percentage of dephosphorylated peptide in the mixture increases, thus validating our hypothesis that dephosphorylation of the peptide enhances proteolytic cleavage, thus releasing the highly fluorescent R110. In other words, there is a direct correlation between the level of dephosphorylated peptide and fluorescence output. To test further whether the phosphopeptide serves as a substrate for the aminopeptidase, we kept the concentration of the nonphosphorylated peptide constant and varied the concentration of the phosphopeptide. The change in fluorescence was found to be proportional to the concentration of the nonphosphorylated peptide in the reaction, with no significant effect of the phosphopeptide on aminopeptidase activity (results not shown). These results confirm the validity of our approach for monitoring the dephosphorylation of phosphopeptides by the cognate enzymes. We then tested the effect of various concentrations of several PPases on the dephosphorylation of the S/T phosphopeptide substrate using peptidase cleavage and fluorescence output as a readout for PPase activity. Here we show the results we obtained with typical PPases, PP1 and PP2A. As shown in Figure 3 , there was a corresponding increase in the fluorescence output with increasing enzyme concentrations. The amounts of enzyme required to dephosphorylate 50% (EC 50 ) of the phosphopeptide by PP1 and PP2A are very low (EC 50 = 6.98 mU for PP1 and 3.28 mU for PP2A), and it is apparent that as low as 1 mU can be detected (Fig.  3) . Similar patterns were obtained with other S/T PPases such as PP2B and PP2C (results not shown). We also investigated the effect of substrate on phosphatase activity of PP2A to determine the Km value for the phosphopeptide substrate. As shown in Figure 4 , the phosphopeptide appears to be an optimal substrate for the enzyme, as indicated by the low Km value (2.2 µM, Fig. 4 ). The assay is versatile, and the activity of these enzymes can be tested at 30°C or 25°C in a single tube or 96-well or 384-well formats. The reaction volume in the 384-well plates was one-fifth of that used in the 96-well plates and thus offers tremendous saving on the cost of reagents, particularly the amount of enzymes used per assay. To assess the reproducibility and robustness of the assay, we measured the Z′ value, which is a measure of data scatter and reproducibility of the assay. A Z′ value of 0.5 or higher is considered acceptable for use in HTS. 16 The results obtained with PP1 in 384-well plates shown in Figure 5 indicate reproducibility of the assay because we consistently get Z′ values of more than 0.8 (Fig.  5) . Similar values were obtained with PP2A, PP2B, and PP2C (data not shown).
We also tested the effect of known selective protein phosphatase inhibitors on their cognate enzymes. As shown in Figure 6 , the IC 50 value (concentration to inhibit the phosphatase activity by 50%) of okadaic acid for PP2A was 0.49 nM, whereas inhibitor-2 does not inhibit its activity. However, inhbitor-2 potently inhibited PP1 (IC 50 = 7.49 nM), whereas okadaic acid was less potent than with PP2A. These IC 50 values for both inhibitors are similar to those obtained by others. 17 
Phosphatase assay with protein tyrosine phosphatases (PTPases)
Because our goal is to develop a phosphatase assay system that is applicable to a broad range of protein phosphatases, the system was also tested for several protein tyrosine phosphatases. These enzymes either are present in the soluble form, such as PTP1B, or are present as a component of large molecular structures, such as CD45 and LAR, or enzymes of bacterial origin, such as Yop51.
Here we show data generated with PTP1B as a prototype of the PTPases, and similar profiles were obtained with CD45 and Yop51 (data not shown).
To determine the activity of PTPases, we used a R110-bis (phosphotyrosine peptide amide) and purified PTP1B in the appropriate buffer, which is described in the Methods section. The results shown in Figure 7 clearly indicate that there is a corresponding increase in fluorescence output with increasing enzyme concentration, with an EC 50 of 0.48 mU. Thus, this assay is sensitive to low concentrations of phosphatases, and when we tested vanadate, the classical and potent inhibitor for PTPases against PTP1B, we obtained an IC 50 of 40 nM (Fig. 8) .
Stability of the signal
To screen a large number of compounds against a phosphatase target, the investigator might have to carry out the assay in a large number of plates, and thus there is a need to terminate the reaction at a precise time point so that the signal can be read at a later time. Toward this goal, we carried out the reactions as usual for the desired time, reactions were terminated, the signal was read (time zero), and fluorescence output was normalized to 100%. The signal was read again 4 h after termination, and the fluorescence output was compared to time zero. The signal output for the enzyme activity did not vary by more than 10%, indicating signal stability for at least 4 h (results not shown). Consequently, the stability of the signal should enable scientists to do batch plate assays, where the signal generated from various plates can be read at a later time point. 6 . Effect of inhibitors on the phosphatase activity of PP2A and PP1. Inhibitor titration profile of known inhibitors of PP2A and PP1 was carried out as described under Methods and in Figure 2 , except using the indicated amount of okadaic acid (black squares) and PP1 inhibitor-2 (gray triangles). The reactions were carried out in solid black 96-well plates using 5 µM Ser/Thr phosphatase peptide substrate and 10 mU PP2A/well (top panel) or 31.25 mU PP1/well (bottom panel). Note that PP1 inhibitor-2 does not affect PP2A activity but strongly inhibits PP1 activity. Also, note that okadaic acid strongly inhibits the activity of PP2A (< 10 nM), whereas it is only weakly effective at inhibiting PP1 activity (> 100 nM). All data points are the average of 4 determinations, and error bars are ± standard deviation. 
Identification of false positives
To have a proven assay for screening compounds toward various phosphatases, the assay should have minimal false hits to ensure reliable results. Toward this goal, we addressed the effect of compounds on the 2 major components of our assay (i.e., the phosphatase and the protease). If a compound inhibits the phos-phatase and does not inhibit the protease, it will result in a decrease in fluorescence, and that is considered a positive hit, which is desirable. However, if the compound inhibits both the phosphatase and the protease, no increase in fluorescence will be observed, but the results are acceptable because such a compound will not be desirable due to lack of specificity. If the compound does not inhibit the phosphatase and the protease, no change in fluorescence will be observed, which is also of no consequence. The only case in which a problem may arise is when the compound does not inhibit phosphatase but inhibits the protease; this will then result in a low signal, and thus such a compound would be selected as a potential drug (false positive). To address this point, we included another peptide, alanine-alanine-phenylalanine linked to 7-amino-4methylcoumarin (AAF-AMC), in our assay to eliminate misinterpretation of the results. This second fluorogenic compound serves as a substrate for protease, but because it does not contain any phosphoamino acid, its cleavage is independent of the phosphatase activity. The cleavage of the peptide results in the formation of free AMC, which can be quantified by excitation at 360 nm and emission at 460 nm. The emission wavelength (460 nm) is well separated from the emission of R110 (530 nm). Therefore, the activities of the phosphatase and protease on the R110-containing peptide can be differentiated from the activity of the protease alone on the AMC-containing peptide. Thus, if a compound inhibits the protease, we should observe a decrease in the emission of both coumarin (460 nm) and rhodamine 110 (530 nm); if the compound does not inhibit the protease but inhibits the phosphatase, no change in the fluorescence at 530 nm with an increase in fluorescence at 460 nm is expected. This should aid in eliminating the potential of generating false hits. The results in Figure 9 show the fluorescence output at 460 nm and 530 nm for the various combinations of these cases. Thus, the use of the second substrate with the phosphatase substrate in the same reaction, or screening for the protease after screening against phosphatase in separate reactions, will ensure the validity of the positive hits that is necessary for developing potential drugs. It is noteworthy that the inclusion of the AAF-AMC peptide in the phosphatase reaction does not alter the kinetics or the activity profile of any of the phosphatases tested (results not shown). The effects of additives that may be present in phosphatase reactions were also investigated. The presence of dimethylsulfoxide (DMSO), which is commonly used as a solvent for dissolving library compounds, was tolerated up to 2%, with less than 25% loss of enzyme activity. Other additives, such as beta-mercaptoethanol (100 µM) and 1% glycerol, gave less than 5% inhibition, whereas 100 µM dithiothreitol (DTT) gave less than 15% inhibition.
In summary, we have developed an assay system that offers the simplicity, sensitivity, and specificity required for developing novel inhibitors of protein phosphatases. Furthermore, the assay is robust with a high Z′ value, nonradioactive, and homogeneous. It can be performed in single tubes and in 96-well plates, 384-well plates, and possibly 1536-well plates. The assay can be performed in as little as 2 h and can be done with just 2 reagent additions. The The assay was carried out as described in Figure 5 , except for the addition of various concentrations of sodium vanadate. The assay was performed in solid black 96-well plates using 5 µM phosphotyrosine phosphatase peptide substrate and 1.25 mU PTP1B/well (specific activity = 20 µmol of hydrolyzed substrate per mg/min at 30°C, pH 7.2). All data points are the average of 4 determinations, and error bars are ± standard deviation. It is apparent from the value obtained (IC 50 value of 40 nM) that sodium vanadate is a potent inhibitor of PTPases. signal-to-background ratio is very high (S/B = 40) compared to other assays (S/B = 2-3 for FP), and the generated signal is very stable for hours after completion of the assay. The system has been validated with known selective inhibitors of protein phosphatases, and the assay can be used as a tool in drug discovery.
DISCUSSION
The completion of the human genome project and the genomes of other organisms, the technological breakthroughs in the design and generation of millions of compounds via combinatorial chemical libraries, and the large number of natural products have height-ened the demands for high-throughput enzyme assays. More efficient and specific assays adaptable to HTS will address this need. Protein kinases and phosphatases have been identified by many pharmaceuticals as valid targets for drug discovery. Because of the large number of enzymes that belong to these 2 classes of enzymes, it is important to develop assay systems that are not only sensitive, but also homogeneous, fast, simple, and cost-effective. The system we describe here meets all of these criteria. In comparison with other high-throughput assays for protein phosphatases, our system can be carried out conveniently and in as a short period as 2 h. Our system circumvents the need for radiolabeled substrates, eliminating the cost of disposing radioactive material. The system does not require antibodies, which not only is a major cost factor, but also introduces additional factors that have to be seriously considered for reproducibility of the results obtained with other systems. These include the selectivity and avidity of the antibodies to the phosphorylated substrate. Furthermore, one cannot predict the appropriate position and spatial arrangement for introduction of the label into the probe, thus requiring significant assay optimization. In addition, reaction components may also influence the binding of the antibodies toward the phosphorylated substrates. These problems are inherent to FP, FRET, and homogeneous timeresolved fluorescence (HTRF), in which the quality of the antibodies is the major factor in assay performance. In comparison with other traditionally used approaches such as colorimetric assays, the technology presented is more sensitive, and thus a significantly lower amount of enzymes and substrates can be used. This is so critical for large-scale assays commonly practiced in drug discoveries, in which large libraries of compounds are tested. The malachite green assay also suffers from interference from inorganic phosphate present in solutions and glassware. The use of pNPP as a substrate for PTPases might not be appropriate because the compound is not similar to the natural substrates commonly encountered in cells. A recent report showed that a novel, low-molecular weight PTPase was capable of hydrolyzing the phosphoester bond in pNPP but could not dephosphorylate phosphopeptide substrates. 9 Thus, caution must be exercised when using nonphosphopeptide substrates. The most recent usage of 3,6-fluorescein diphosphate as a substrate for PTPases imparts higher sensitivity but is limited to only the PTPase class of phosphatases, and it is not specific because other nonprotein phosphatases (acid and alkaline phosphatases) and other unrelated enzymes such as hydrolases and esterases can use this substrate. The technology we developed can be used to assay specifically PTPases or PPases and will not be affected by hydrolases or esterases. The robustness of the technology we developed is evident by the high Z′ factor obtained using very low concentrations of enzyme. The simplicity of the assay system makes it easy to screen a large number of compounds against a protein phosphatase target in a rapid and very efficient manner, and it can be performed with minimal supervision and with less expensive equipment. Finally, due to the versatility of this approach, we have successfully used a similar strategy for protein 
